Pituitary Tumors: Causes, Symptoms, Diagnosis and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Pituitary tumors — predominantly benign adenomas — are the third most common intracranial tumors (after gliomas and meningiomas), accounting for approximately 15-20% of all intracranial neoplasms and are found incidentally in approximately 10-20% of autopsy studies and 10-38% of MRI scans performed for non-pituitary indications. Clinically apparent pituitary adenomas have an estimated prevalence of approximately 80-100 per 100,000 population. The 2022 WHO Classification replaced the term 'adenoma' with pituitary neuroendocrine tumor (PitNET) to align with neuroendocrine tumor nomenclature, though adenoma remains in common clinical use. Tumors are classified by hormone secretory phenotype — functioning versus non-functioning — and by size: microadenomas (less than 1 cm) versus macroadenomas (1 cm or larger). Prolactinoma (prolactin-secreting) is the most common functioning adenoma, followed by GH-secreting (acromegaly), ACTH-secreting (Cushing's disease), and TSH-secreting tumors. Non-functioning adenomas are the most common overall type requiring surgery.

The vast majority of pituitary adenomas are sporadic, arising from clonal somatic mutations in individual pituitary cells without systemic malignant potential. In GH-secreting somatotroph adenomas, activating somatic mutations in the GNAS gene (encoding Gs-alpha, the stimulatory G-protein alpha subunit) are found in approximately 40% of cases. USP8 gain-of-function mutations are identified in approximately 50-60% of sporadic ACTH-secreting corticotroph adenomas causing Cushing's disease. Hereditary pituitary tumor syndromes account for approximately 5% of cases: multiple endocrine neoplasia type 1 (MEN1, menin gene mutations) causes pituitary adenomas (most commonly prolactinomas and non-functioning adenomas) combined with parathyroid hyperplasia and pancreatic neuroendocrine tumors; Carney complex (PRKAR1A mutations) causes GH-secreting adenomas with atrial myxomas and skin tumors; familial isolated pituitary adenoma (FIPA) is caused by AIP (aryl hydrocarbon receptor interacting protein) mutations in approximately 20% of cases, predominantly causing large GH-secreting adenomas in young patients; and X-linked acrogigantism (XLAG) from GPR101 microduplication causes extreme gigantism in infancy.

Clinical manifestations of pituitary tumors fall into two categories: hormone excess syndromes from functioning tumors and mass effect symptoms from local tumor expansion. Prolactinoma causes hyperprolactinemia manifesting as galactorrhea and menstrual irregularity or amenorrhea in women, and erectile dysfunction, decreased libido, and infertility in men — symptoms frequently present for months to years before diagnosis. GH-secreting adenomas (acromegaly) cause insidious enlargement of hands, feet, and jaw (prognathism), macroglossia, coarsening of facial features, widened spacing of teeth, carpal tunnel syndrome, sleep apnea, and joint arthropathy; gigantism occurs when GH excess precedes epiphyseal closure in children. ACTH-secreting adenomas (Cushing's disease) produce central obesity, purple striae, proximal myopathy, facial plethora, easy bruising, thin skin, hypertension, and osteoporosis. Non-functioning macroadenomas typically present with bitemporal hemianopia (from optic chiasm compression), headache, hypopituitarism (fatigue, cold intolerance, hypogonadism), and sometimes with acute pituitary apoplexy — sudden severe headache, visual loss, and ophthalmoplegia from tumor hemorrhage or infarction.

Brain MRI with gadolinium using dedicated thin-section (3 mm) coronal pituitary protocol is the gold standard imaging modality for detection and localization of pituitary adenomas, including small microadenomas as small as 2-3 mm. Hormonal evaluation is comprehensive and subtype-specific: serum prolactin (baseline and after hook effect dilution for very large tumors); IGF-1 and oral glucose tolerance test with GH suppression for acromegaly; 24-hour urinary free cortisol (UFC), late-night salivary cortisol, and 1 mg overnight dexamethasone suppression test for Cushing's syndrome (followed by inferior petrosal sinus sampling — IPSS — for Cushing's disease confirmation and lateralization when pituitary MRI is non-localizing or ambiguous); TSH, free T4, LH, FSH, testosterone or estradiol, and morning cortisol for pituitary insufficiency. Formal Humphrey visual field perimetry quantifies chiasmal compression.

Treatment is subtype-specific. Prolactinomas: cabergoline (dopamine agonist, 0.25-0.5 mg twice weekly, titrated to normalize prolactin) is the first-line therapy and successfully normalizes prolactin in over 90% and shrinks macroadenomas significantly, often recovering chiasmal vision. Bromocriptine is an alternative in pregnancy planning. Surgery is reserved for cabergoline-resistant or intolerant cases. For GH-secreting adenomas (acromegaly): transsphenoidal surgery is first-line, achieving remission in approximately 75-80% of microadenomas and 40-50% of macroadenomas. Adjuvant somatostatin receptor ligands (octreotide LAR, lanreotide autogel), pegvisomant (GH receptor antagonist), or radiosurgery manage surgical failures. For Cushing's disease (ACTH-secreting): transsphenoidal surgery is first-line with remission in 65-90% at experienced centers; bilateral adrenalectomy for surgical failures; pasireotide (multireceptor somatostatin analog) or mifepristone (glucocorticoid receptor antagonist) for medical management. Non-functioning macroadenomas with chiasmal compression or hypopituitarism: transsphenoidal surgery; surveillance with MRI for small non-compressive tumors. Stereotactic radiosurgery (Gamma Knife, CyberKnife) treats surgical remnant or recurrence.

No preventive measures exist for sporadic pituitary adenomas. For patients with known hereditary syndromes, systematic screening enables earlier diagnosis. MEN1 patients should undergo annual pituitary MRI and prolactin/GH/IGF-1 testing starting at age 5. AIP mutation carriers (FIPA syndrome) should have pituitary MRI and IGF-1 testing every 2 years from early adulthood due to the predominant GH-secreting adenoma phenotype. Incidentally discovered pituitary masses (incidentalomas) found on MRI require biochemical evaluation to exclude functioning tumor and visual field assessment for macroadenomas, followed by interval MRI surveillance for non-functioning microadenomas (every 1-2 years for the first 3 years, then as directed by pituitary multidisciplinary team). No population-level screening for pituitary tumors is recommended.

Any woman with unexplained menstrual irregularity or cessation combined with milky nipple discharge (galactorrhea) not related to pregnancy or breastfeeding should have serum prolactin measured and a pituitary MRI if prolactin is elevated. A man with erectile dysfunction, loss of libido, or unexplained infertility should have prolactin and testosterone measured. Any patient with new progressive visual loss — particularly a pattern where the outer peripheral fields are affected in both eyes simultaneously — requires urgent ophthalmology and endocrinology referral to exclude pituitary macroadenoma compressing the optic chiasm. Sudden severe headache with visual disturbances or ophthalmoplegia may represent pituitary apoplexy and is a neurological emergency requiring same-day MRI. Patients with characteristic features of acromegaly (progressive enlargement of hands, jaw, or feet in an adult) or Cushing's syndrome (new-onset central obesity, purple striae, proximal weakness) should be referred to an endocrinologist for detailed hormonal investigation.

Prolactinomas: normalization of prolactin with cabergoline in over 90%. Cushing's disease: surgical remission in 65-90% at experienced centers with approximately 25-30% recurrence at 5 years. GH adenoma: biochemical remission after surgery in approximately 75-80% of microadenomas. Pituitary carcinoma: very rare, very poor prognosis with median survival approximately 3-4 years. Non-functioning adenoma regrowth: approximately 10-15% per year without adjuvant radiosurgery. The prognosis for Pituitary Tumors: Causes, Symptoms, Diagnosis and Treatment varies depending on the severity of the condition at diagnosis, the patient's overall health, and how promptly treatment is initiated. With early diagnosis and appropriate management, many patients with Pituitary Tumors: Causes, Symptoms, Diagnosis and Treatment achieve good outcomes and can maintain quality of life. Regular follow-up with healthcare providers is essential to monitor progress, adjust treatment as needed, and detect any complications early. Adherence to prescribed treatments and lifestyle modifications significantly improves long-term prognosis.